Processing

Please wait...

Settings

Settings

Goto Application

1. US20210388031 - Designer Peptide Opsonins

Office
United States of America
Application Number 17348994
Application Date 16.06.2021
Publication Number 20210388031
Publication Date 16.12.2021
Publication Kind A1
IPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
G16B 15/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
CPC
C07K 2319/735
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
70containing domain for protein-protein interaction
735containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
G16B 15/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Applicants New Jersey Institute of Technology
Inventors Dr. Vivek A. Kumar
Title
(EN) Designer Peptide Opsonins
Abstract
(EN)

Disclosed is a new strategy, composition, and method for a self-assembling peptides (SAP) that will self-assemble atop COVID-19 for immune destruction and act as a functional COVID-19 opsonin. The designed self-assembling peptides bind and assemble atop SARS-CoV-2—providing a new mechanism of infection abrogation. One benefit is avoidance of side effects that other formulations or repurposed drugs contain. Other feature of this technology include: (a) (SAP) are composed of L-amino acids that are highly biocompatible sub-Q, IM and IV (no adverse reaction for 10% blood volume replacement with 1 w % peptide in mice or rats); (b) Highly targeted approach that binds to viral particles preventing side effects; (c) SAP are intrinsically biodegradable and endocytosed; (d) SAP bound COVID-19 may promote engulfment, clearance, and antigen presentation (for immunity development); and (e) targeting the spike protein with SAP may allow treatment of other coronaviruses.